This company is one of the most insulated companies from tariffs and perhaps even a recession. It is a behemoth in the healthcare sector and derives the vast majority of its revenue from U.S. healthcare services. The company has little to lose from a trade war, and even if the pharmaceutical industry hikes prices, it can easily pass those on to its customers.
Analysts project consistent growth going forward and this growth is unlikely to be knocked down even if a recession hits or tariffs stick around. As a result, this stock has performed remarkably well compared to the rest of the market.
This post originally appeared at Money Morning.